COMMUNIQUÉS West-GlobeNewswire

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

13/09/2024 - 22:30

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13/09/2024 - 22:30

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

KKR to Purchase of 11,619,998 Shares of BrightSpring Health Services Common Stock from Walgreens Boots Alliance

13/09/2024 - 22:00

LOUISVILLE, Ky., Sept. 13, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, [...]

Fagron completes share buy-back program

13/09/2024 - 18:28

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last [...]

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

13/09/2024 - 18:15

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the [...]

Virbac : Rapport financier semestriel 2024

13/09/2024 - 18:15

Ci-joint le rapport financier semestriel 2024 de Virbac Pièce jointe Rapport financier semestriel_2024 pour publication

Virbac : Half-yearly financial report 2024

13/09/2024 - 18:15

Please find attached 2024 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2024 for publication

Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

13/09/2024 - 18:15

Public release of the Half-Year Financial Report at 30 June 2024. The Group released and filed its 2024 half-year financial report with the French “Autorité des marchés financiers”. The document is also available on the [...]

Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2024.

13/09/2024 - 18:15

Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2024. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier [...]

Le traitement prophylactique par dexaméthasone réduit les réactions liées à la perfusion chez les patients atteints d'un cancer du poumon non à petites cellules avancé muté EGFR et traités par RYBREVANT® ▼ (amivantamab) par voie intraveineu

13/09/2024 - 18:09

La prémédication à une dose de 8 mg à entraîné un taux de réaction lié à la perfusion de 22,5 pour cent avec l'amivantamab par voie intraveineuse, soit trois fois moins que le taux de 67,4 pour cent historiquement [...]

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

13/09/2024 - 18:05

KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that [...]

Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

13/09/2024 - 17:45

During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders’ meeting on June 20, 2023, decided to reduce the share capital of Virbac by [...]

Virbac : le conseil d’administration annonce une réduction de capital par voie d’annulation d’actions propres

13/09/2024 - 17:45

Le conseil d’administration réuni le 13 septembre 2024 a, sur autorisation de l’assemblée générale mixte du 20 juin 2023, décidé de réduire le capital social de Virbac par voie d’annulation de 67 340 actions propres. [...]

Virbac: Information on the departure of Sébastien Huron

13/09/2024 - 17:45

At its meeting on September 13, 2024, the board of directors acknowledged the resignation of Sébastien Huron, effective as of September 27, 2024, from his positions as chief executive officer of Virbac and director of [...]

Virbac: Informations sur les conditions de départ de Sébastien Huron

13/09/2024 - 17:45

Lors de sa réunion du 13 septembre 2024, le conseil d’administration a constaté la démission de Sébastien Huron, avec effet au 27 septembre 2024, de son mandat de directeur général de Virbac et d'administrateur de [...]

Virbac 2024 half-year results

13/09/2024 - 17:45

Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange rates Strong growth in adjusted current operating income 1 +3.4 points compared with 2023 to reach a record level at 21.4% of [...]

Virbac: résultats semestriels 2024

13/09/2024 - 17:45

Dynamique d’activité exceptionnelle sur le premier semestre avec un chiffre d’affaires en progression de 16,1% à taux de change constants Résultat opérationnel courant ajusté 1 en forte progression +3,4 points par [...]

Disclosure of large shareholding and mandatory notification of trade in Vistin Pharma ASA

13/09/2024 - 17:10

Saga Pure ASA has on 13 September 2024 purchased 250,000 shares in Vistin Pharma ASA at NOK 25.13 per share. After the transaction Saga Pure ASA has a holding of 650,000 shares, corresponding to 1.47% ownership. Saga [...]

Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

13/09/2024 - 17:01

Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a [...]